Klaas Kok

8.9k citations

128 papers · 4.4k indexed · h-index 38

Cancer Research top 1%
- Cancer Genomics and Diagnostics 26
- MicroRNA in disease regulation 15
- Cancer-related molecular mechanisms research 13
Molecular Biology top 2%
- RNA modifications and cancer 24
- Renal and related cancers 15
Oncology top 2%
Genetics top 2%
- Genomic variations and chromosomal abnormalities 27
Pathology and Forensic Medicine top 2%
- Genetic factors in colorectal cancer 13
Pulmonary and Respiratory Medicine
- Lung Cancer Treatments and Mutations 19

Co-authors: Anke van den Berg C.H.C.M. Buys Susan L. Naylor Charles H.C.M. Buys Gerben Duns B. Carritt Robert M.W. Hofstra Sibrand Poppema
Cited by: Cancer Research Molecular Biology Oncology
Journals: Nature (1 paper)Proceedings of the National Academy of Sciences (1 paper)Nucleic Acids Research (3 papers)
Partner nations: Netherlands United States Germany

In The Last Decade

Klaas Kok

123 papers receiving 4.3k citations

Peers

Countries citing papers authored by Klaas Kok

Since Specialization

Citations

This map shows the geographic impact of Klaas Kok's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Klaas Kok with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Klaas Kok more than expected).

Fields of papers citing papers by Klaas Kok

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Klaas Kok. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Klaas Kok. The network helps show where Klaas Kok may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Klaas Kok, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Klaas Kok Line = papers co-authored together Klaas Kok links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Profiling of driver mutations in lung adenocarcinoma patients identifies rare compound EGFR mutations sensitive to second-generation EGFR-TKIs SHILAP Revista de lepidopterología ·Jun Li,Cuiyun Zhang,Yuping Guan,Siyu Wang,Jiawen Zheng,Junnan Feng,Sile Han,Ruijuan Ma,Pengfei Ren,Shasha Li,Henk Groen,Klaas Kok,Anke van den Berg,Bing Wei,Jie Ma,Hongle Li,Yongjun Guo	2024	0
2	An mRNA expression-based signature for oncogene-induced replication-stress Oncogene ·Sergi Guerrero Llobet,Arkajyoti Bhattacharya,Marieke Everts,Klaas Kok,Bert van der Vegt,Rudolf S.N. Fehrmann,Marcel A.T.M. van Vugt	2022	26
3	Low Mutational Burden of Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue in Patients with Primary Sjogren’s Syndrome Cancers ·Johanna Bult,Jéssica Rodrigues Plaça,Erlin A. Haacke,Martijn Terpstra,Gwenny M. Verstappen,Fred K. L. Spijkervet,Frans G. M. Kroese,Wouter J. Plattel,Joost S.P. Vermaat,Hendrika Bootsma,Bert van der Vegt,Arjan Diepstra,Anke van den Berg,Klaas Kok,Marcel Nijland	2022	9
4	Evaluation of a seven gene mutational profile as a prognostic factor in a population-based study of clear cell renal cell carcinoma Scientific Reports ·Jeroen A. A. van de Pol,Paranita Ferronika,Helga Westers,Manon van Engeland,Martijn Terpstra,Kim M. Smits,Kim de Lange,Piet A. van den Brandt,Rolf H. Sijmons,Leo J. Schouten,Klaas Kok	2022	4
5	An All-In-One Transcriptome-Based Assay to Identify Therapy-Guiding Genomic Aberrations in Nonsmall Cell Lung Cancer Patients Cancers ·Jiacong Wei,Anna A. Rybczynska,Pei Meng,Martijn Terpstra,Ali Saber,Jantine Sietzema,Wim Timens,Ed Schuuring,T. Jeroen N. Hiltermann,Harry J.M. Groen,Anthonie J. van der Wekken,Anke van den Berg,Klaas Kok	2020	9
6	Cellular senescence impairs the reversibility of pulmonary arterial hypertension Science Translational Medicine ·Diederik E. van der Feen,Guido P. L. Bossers,Quint A. J. Hagdorn,Jan-Renier Moonen,Kondababu Kurakula,Robert Szulcek,James Chappell,Francesco Vallania,Michele Donato,Klaas Kok,Jaskaren Kohli,Arjen H. Petersen,Tom van Leusden,Marco Demaria,Marie‐José Goumans,Rudolf A. de Boer,Purvesh Khatri,Marlene Rabinovitch,Rolf M.F. Berger,Beatrijs Bartelds	2020	85
7	Comprehensive Profiling of Primary and Metastatic ccRCC Reveals a High Homology of the Metastases to a Subregion of the Primary Tumour Cancers ·Paranita Ferronika,Joost Hof,Gürsah Kats‐Ugurlu,Rolf H. Sijmons,Martijn Terpstra,Kim de Lange,Anna M. Leliveld,Helga Westers,Klaas Kok	2019	14
8	Differential miRNA Expression Profiles in Cumulus and Mural Granulosa Cells from Human Pre-ovulatory Follicles MicroRNA ·Daniela Andrei,Roland Nagy,Aafke P.A. van Montfoort,Uwe J.F. Tietge,Martijn Terpstra,Klaas Kok,Anke van den Berg,Annemieke Hoek,Joost Kluiver,Rogier B. Donker	2018	29
9	Argonaute 2 RNA Immunoprecipitation Reveals Distinct miRNA Targetomes of Primary Burkitt Lymphoma Tumors and Normal B Cells American Journal Of Pathology ·Agnieszka Dzikiewicz‐Krawczyk,Arjan Diepstra,Bea Rutgers,Gertrud Kortman,Debora de Jong,Jasper Koerts,Marian Bulthuis,Tineke van der Sluis,Annika Seitz,Lydia Visser,Klaas Kok,Joost Kluiver,Anke van den Berg	2018	6
10	DNA and RNA analysis of intratumour heterogeneity in metastatic clear cell renal cell carcinoma Annals of Oncology ·Paranita Ferronika,Joost Hof,Gürsah Kats‐Ugurlu,Miente Martijn Terpstra,Kim de Lange,Anna M. Leliveld,Rolf H. Sijmons,Klaas Kok	2017	2
11	Genomic Aberrations in Crizotinib Resistant Lung Adenocarcinoma Samples Identified by Transcriptome Sequencing PLoS ONE ·Ali Saber,Anthonie J. van der Wekken,Klaas Kok,Martijn Terpstra,Lisette J. Bosman,Mirjam F. Mastik,Wim Timens,Ed Schuuring,T. Jeroen N. Hiltermann,Harry J.M. Groen,Anke van den Berg	2016	13
12	Towards Sustained Silencing of HER2/neu in Cancer By Epigenetic Editing Molecular Cancer Research ·Fahimeh Falahi,Christian Huisman,Hinke G. Kazemier,Pieter van der Vlies,Klaas Kok,Geke A.P. Hospers,Marianne G. Rots	2013	60
13	Copy number gain at 8q12.1‐q22.1 is associated with a malignant tumor phenotype in salivary gland myoepitheliomas Genes Chromosomes and Cancer ·Hedy Vékony,Kerstin Röser,Thomas Löning,Bauke Ylstra,Gerrit A. Meijer,Wessel N. van Wieringen,Mark A. van de Wiel,Beatriz Carvalho,Klaas Kok,C. René Leemans,I. van der Waal,Elisabeth Bloemena	2008	13
14	Amplicon Mapping and Expression Profiling Identify the Fas-Associated Death Domain Gene as a New Driver in the 11q13.3 Amplicon in Laryngeal/Pharyngeal Cancer Clinical Cancer Research ·Johan H. Gibcus,Lorian Menkema,Mirjam F. Mastik,Mario Hermsen,Geertruida H. de Bock,Marie‐Louise F. van Velthuysen,Robert P. Takes,Klaas Kok,César Marcos,Bernard F. A. M. van der Laan,Michiel W. M. van den Brekel,Johannes A. Langendijk,Philip M. Kluin,Jacqueline E. van der Wal,Ed Schuuring	2007	74
15	Mechanisms and Effects of Loss of Human Leukocyte Antigen Class II Expression in Immune-Privileged Site-Associated B-Cell Lymphoma Clinical Cancer Research ·Marije Booman,Jenny Douwes,Annuska M. Glas,Sietske A. Riemersma,Ekaterina S. Jordanova,Klaas Kok,Andreas Rosenwald,Daphne de Jong,Ed Schuuring,Philip M. Kluin	2006	53
16	BCL6 alternative breakpoint region break and homozygous deletion of 17q24 in the nodular lymphocyte predominance type of Hodgkin's lymphoma–derived cell line DEV Human Pathology ·Çiğdem Atayar,Klaas Kok,Joost Kluiver,Anneke Bosga,Eva van den Berg,Pieter van der Vlies,Tjasso Blokzijl,Geert Harms,Inge Davelaar,Birgit Sikkema‐Raddatz,José I. Martı́n-Subero,Reiner Siebert,Sibrand Poppema,Anke van den Berg	2006	24
17	Application of a comprehensive subtelomere array in clinical diagnosis of mental retardation European Journal of Medical Genetics ·Klaas Kok,Trijnie Dijkhuizen,Yolanthe Swart,Hanny Zorgdrager,Pieter van der Vlies,Rudolf S.N. Fehrmann,Gerard J. te Meerman,Klasien B.J. Gerssen‐Schoorl,Ton van Essen,Birgit Sikkema‐Raddatz,Charles H.C.M. Buys	2005	26
18	Substantial reduction of the gastric carcinoma critical region at 6q16.3-q23.1 Genes Chromosomes and Cancer ·Beatriz Carvalho,Raquel Seruca,Fátima Carneiro,Charles H.C.M. Buys,Klaas Kok	1999	19
19	Localization of amplified c-myc and n-myc in small cell lung cancer cell lines Cancer Genetics and Cytogenetics ·Annemarie H. van der Hout,Klaas Kok,Anneke Y. van der Veen,Jan Osinga,Lou F. M. H. de Leij,Charles H.C.M. Buys	1989	13
20	Direct molecular analysis of a deletion of 3p in tumors from patients with sporadic renal cell carcinoma Cancer Genetics and Cytogenetics ·Annemarie H. van der Hout,Klaas Kok,Anke van den Berg,J. Wolter Oosterhuis,B. Carritt,Charles H.C.M. Buys	1988	33

About Klaas Kok

Klaas Kok is a scholar working on Cancer Research, Pathology and Forensic Medicine and Molecular Biology, having authored 128 papers that have together received 4.4k indexed citations. Recurring topics across this work include Genomic variations and chromosomal abnormalities (27 papers), Cancer Genomics and Diagnostics (26 papers), RNA modifications and cancer (24 papers), Lung Cancer Treatments and Mutations (19 papers), MicroRNA in disease regulation (15 papers), Renal and related cancers (15 papers), Cancer-related molecular mechanisms research (13 papers) and Genetic factors in colorectal cancer (13 papers). The work is most often cited by research in Cancer Research (1.3k citations), Molecular Biology (2.9k citations) and Oncology (1.0k citations). Klaas Kok has collaborated with scholars based in Netherlands, United States and Germany. Frequent co-authors include Anke van den Berg, C.H.C.M. Buys, Susan L. Naylor, Charles H.C.M. Buys, Gerben Duns, B. Carritt, Robert M.W. Hofstra, Sibrand Poppema, Anneke Y. van der Veen and Harry J.M. Groen. Their work appears in journals such as Nature, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact